The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow A correction has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Related articles in The JI
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, Z.
Right arrow Articles by Nussenblatt, R. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, Z.
Right arrow Articles by Nussenblatt, R. B.
Right arrowPubmed/NCBI databases
*Substance via MeSH
The Journal of Immunology, 2005, 174: 5187-5191.
Copyright © 2005 by The American Association of Immunologists


CUTTING EDGE

Cutting Edge: In Vivo Blockade of Human IL-2 Receptor Induces Expansion of CD56bright Regulatory NK Cells in Patients with Active Uveitis

Zhuqing Li*, Wee Kiak Lim1,*,{dagger}, Sankaranarayana P. Mahesh*, Baoying Liu* and Robert B. Nussenblatt2,*

* Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892; and {dagger} Singapore National Eye Center, Singapore

In vivo blockade of the human IL-2R by mAb has been used for immunosuppression in transplantation, therapy for leukemia, and autoimmune diseases. In this study, we report that administration of a humanized IL-2R blocking Ab induced a 4- to 20-fold expansion of CD56bright regulatory NK cells in uveitis patients over time. The induced CD56bright regulatory NK cells from patients exhibited similar phenotype as those naturally occurring CD56bright cells. Patients with active uveitis had a significantly lower level of CD56bright NK cells compared with normal donors (p < 0.01). In addition, the induced CD56bright cells could secrete large amounts of IL-10 whereas CD56dim NK cells could not, suggesting that the induction of the CD56bright cells may have a beneficial effect on the remission of active uveitis. Our observation may have implications to IL-2R blockade therapy and for the potential role of CD56bright regulatory NK cells in autoimmune diseases.


Related articles in The JI:

Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56bright regulatory NK cells in patients with active uveitis
Z. Li, W. K. Lim, S. P. Mahesh, B. Liu, and R. B. Nussenblatt
The JI 2005 175: 3447. [Full Text]  



This article has been cited by other articles:


Home page
Arch OphthalmolHome page
S. Yeh, Z. Li, F. Forooghian, F. S. Hwang, M. A. Cunningham, S. Pantanelli, J. C. Lew, K. K. Wroblewski, S. Vitale, and R. B. Nussenblatt
CD4+Foxp3+ T-Regulatory Cells in Noninfectious Uveitis
Arch Ophthalmol, April 1, 2009; 127(4): 407 - 413.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Chen, M. Zhang, W. Ju, and T. A. Waldmann
Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25
Blood, February 5, 2009; 113(6): 1287 - 1293.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
J. D. Lunemann and C. Munz
Do natural killer cells accelerate or prevent autoimmunity in multiple sclerosis?
Brain, July 1, 2008; 131(7): 1681 - 1683.
[Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
T. Kheradmand, P. P. Trivedi, N. A. Wolf, P. C. Roberts, and R. H. Swanborg
Characterization of a subset of bone marrow-derived natural killer cells that regulates T cell activation in rats
J. Leukoc. Biol., May 1, 2008; 83(5): 1128 - 1135.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. Liu, Z. Li, S. P. Mahesh, S. Pantanelli, F. S. Hwang, W. O. Siu, and R. B. Nussenblatt
Glucocorticoid-induced Tumor Necrosis Factor Receptor Negatively Regulates Activation of Human Primary Natural Killer (NK) Cells by Blocking Proliferative Signals and Increasing NK Cell Apoptosis
J. Biol. Chem., March 28, 2008; 283(13): 8202 - 8210.
[Abstract] [Full Text] [PDF]


Home page
Arch OphthalmolHome page
L. Sobrin, J. J. Huang, W. Christen, C. Kafkala, P. Choopong, and C. S. Foster
Daclizumab for Treatment of Birdshot Chorioretinopathy
Arch Ophthalmol, February 1, 2008; 126(2): 186 - 191.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
P. B. Silver, R. K. Agarwal, S.-B. Su, I. Suffia, R. S. Grajewski, D. Luger, C.-C. Chan, R. M. Mahdi, J. M. Nickerson, and R. R. Caspi
Hydrodynamic Vaccination with DNA Encoding an Immunologically Privileged Retinal Antigen Protects from Autoimmunity through Induction of Regulatory T Cells
J. Immunol., October 15, 2007; 179(8): 5146 - 5158.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. T. Snyder, J. Shen, H. Azmi, J. Hou, D. H. Fowler, and J. A. Ragheb
Direct inhibition of CD40L expression can contribute to the clinical efficacy of daclizumab independently of its effects on cell division and Th1/Th2 cytokine production
Blood, June 15, 2007; 109(12): 5399 - 5406.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
D. Huang, F.-D. Shi, S. Jung, G. C. Pien, J. Wang, T. P. Salazar-Mather, T. T. He, J. T. Weaver, H.-G. Ljunggren, C. A. Biron, et al.
The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system
FASEB J, May 1, 2006; 20(7): 896 - 905.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.